Literature DB >> 33060199

Unusual zwitterionic catalytic site of SARS-CoV-2 main protease revealed by neutron crystallography.

Daniel W Kneller1,2, Gwyndalyn Phillips1,2, Kevin L Weiss1,2, Swati Pant1,2, Qiu Zhang1,2, Hugh M O'Neill1,2, Leighton Coates3,2,4, Andrey Kovalevsky3,2.   

Abstract

The main protease (3CL Mpro) from SARS-CoV-2, the etiological agent of COVID-19, is an essential enzyme for viral replication. 3CL Mpro possesses an unusual catalytic dyad composed of Cys145 and His41 residues. A critical question in the field has been what the protonation states of the ionizable residues in the substrate-binding active-site cavity are; resolving this point would help understand the catalytic details of the enzyme and inform rational drug development against this pernicious virus. Here, we present the room-temperature neutron structure of 3CL Mpro, which allowed direct determination of hydrogen atom positions and, hence, protonation states in the protease. We observe that the catalytic site natively adopts a zwitterionic reactive form in which Cys145 is in the negatively charged thiolate state and His41 is doubly protonated and positively charged, instead of the neutral unreactive state usually envisaged. The neutron structure also identified the protonation states, and thus electrical charges, of all other amino acid residues and revealed intricate hydrogen-bonding networks in the active-site cavity and at the dimer interface. The fine atomic details present in this structure were made possible by the unique scattering properties of the neutron, which is an ideal probe for locating hydrogen positions and experimentally determining protonation states at near-physiological temperature. Our observations provide critical information for structure-assisted and computational drug design, allowing precise tailoring of inhibitors to the enzyme's electrostatic environment.
© 2020 Kneller et al.

Entities:  

Keywords:  3CL Mpro; 3CL main protease; SARS–CoV-2; SARS–CoV-2 3CL main protease; X-ray crystallography; drug design; enzyme mechanism; hydrogen bond; joint neutron; neutron diffraction; protonation state; room temperature; viral protease

Mesh:

Substances:

Year:  2020        PMID: 33060199     DOI: 10.1074/jbc.AC120.016154

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen.

Authors:  Maria Kuzikov; Elisa Costanzi; Jeanette Reinshagen; Francesca Esposito; Laura Vangeel; Markus Wolf; Bernhard Ellinger; Carsten Claussen; Gerd Geisslinger; Angela Corona; Daniela Iaconis; Carmine Talarico; Candida Manelfi; Rolando Cannalire; Giulia Rossetti; Jonas Gossen; Simone Albani; Francesco Musiani; Katja Herzog; Yang Ye; Barbara Giabbai; Nicola Demitri; Dirk Jochmans; Steven De Jonghe; Jasper Rymenants; Vincenzo Summa; Enzo Tramontano; Andrea R Beccari; Pieter Leyssen; Paola Storici; Johan Neyts; Philip Gribbon; Andrea Zaliani
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-11

2.  The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and x-ray diffraction at room temperature.

Authors:  Galen J Correy; Daniel W Kneller; Gwyndalyn Phillips; Swati Pant; Silvia Russi; Aina E Cohen; George Meigs; James M Holton; Stefan Gahbauer; Michael C Thompson; Alan Ashworth; Leighton Coates; Andrey Kovalevsky; Flora Meilleur; James S Fraser
Journal:  Sci Adv       Date:  2022-05-27       Impact factor: 14.957

Review 3.  Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds.

Authors:  Jiajie Zhu; Haiyan Zhang; Qinghong Lin; Jingting Lyu; Lu Lu; Hanxi Chen; Xuning Zhang; Yanjun Zhang; Keda Chen
Journal:  Drug Des Devel Ther       Date:  2022-04-08       Impact factor: 4.319

4.  Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.

Authors:  Daniel W Kneller; Hui Li; Gwyndalyn Phillips; Kevin L Weiss; Qiu Zhang; Mark A Arnould; Colleen B Jonsson; Surekha Surendranathan; Jyothi Parvathareddy; Matthew P Blakeley; Leighton Coates; John M Louis; Peter V Bonnesen; Andrey Kovalevsky
Journal:  Nat Commun       Date:  2022-04-27       Impact factor: 17.694

Review 5.  Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus.

Authors:  Yustina Hartini; Bakti Saputra; Bryan Wahono; Zerlinda Auw; Friska Indayani; Lintang Adelya; Gabriel Namba; Maywan Hariono
Journal:  Results Chem       Date:  2020-12-25

Review 6.  Structural biology in the time of COVID-19: perspectives on methods and milestones.

Authors:  Miranda L Lynch; Edward H Snell; Sarah E J Bowman
Journal:  IUCrJ       Date:  2021-04-23       Impact factor: 4.769

Review 7.  What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design.

Authors:  Muya Xiong; Haixia Su; Wenfeng Zhao; Hang Xie; Qiang Shao; Yechun Xu
Journal:  Med Res Rev       Date:  2021-01-18       Impact factor: 12.388

8.  Impact of Warhead Modulations on the Covalent Inhibition of SARS-CoV-2 Mpro Explored by QM/MM Simulations.

Authors:  Sergio Martí; Kemel Arafet; Alessio Lodola; Adrian J Mulholland; Katarzyna Świderek; Vicent Moliner
Journal:  ACS Catal       Date:  2021-12-26       Impact factor: 13.084

9.  Asymmetric dynamics of dimeric SARS-CoV-2 and SARS-CoV main proteases in an apo form: Molecular dynamics study on fluctuations of active site, catalytic dyad, and hydration water.

Authors:  Shinji Iida; Yoshifumi Fukunishi
Journal:  BBA Adv       Date:  2021-06-20

10.  Tuning Proton Transfer Thermodynamics in SARS-Cov-2 Main Protease: Implications for Catalysis and Inhibitor Design.

Authors:  Laura Zanetti-Polzi; Micholas Dean Smith; Chris Chipot; James C Gumbart; Diane L Lynch; Anna Pavlova; Jeremy C Smith; Isabella Daidone
Journal:  ChemRxiv       Date:  2020-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.